TG Therapeutics reports five-year analysis shows BRIUMVI lowers disability progression risk vs Roche’s Ocrevus and Novartis’ Kesimpta
Bitget2026/10/12 11:30- TG Therapeutics announced publication of a five-year comparative analysis of Briumvi versus rival anti-CD20 drugs in relapsing multiple sclerosis.
- Results were presented as a peer-reviewed journal publication, not a future conference disclosure.
- Study suggests Briumvi could reduce long-term disability worsening risk versus ocrelizumab or ofatumumab in cross-trial comparisons.
- Analysis also indicates lower relapse activity over time versus ocrelizumab, based on adjusted comparisons rather than head-to-head testing.
- Findings were described as exploratory, highlighting potential differentiation that could support prescribing and market positioning if confirmed directly.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gilead Sciences (GILD.US) acquires PepStar’s oral inflammation drug program for $1.275 billion in cash, increasing investment in inflammatory bowel disease pipeline
Gilead Sciences will acquire PepStar’s anti-inflammatory drug program for $1.28 billions.
Japan's core CPI rose 2.1% year-on-year in September, surpassing the central bank's 2% target for the first time in nine months! Broadening inflation strengthens expectations of a near-term rate hike.
Data released on Friday showed that Japan’s core Consumer Price Index (CPI) rose by 2.1% year-on-year in September, exceeding the Bank of Japan’s 2% inflation target for the first time in nine months. This indicates that price pressures are spreading and reinforces market expectations of an interest rate hike in the near future.
Heatbit launches a new home water heater that can mine Bitcoin
DoubleLine Capital: Large-Scale Borrowing and Weak Demand Will Continue to Put Pressure, Still Bearish on Long-Term U.S. Treasuries
DoubleLine Capital Deputy Chief Investment Officer Jeffrey Sherman stated that he remains bearish on long-term U.S. Treasury bonds, believing that large-scale government borrowing and weak demand will continue to put pressure on the U.S. Treasury market.
Crypto prices
More
